Guiyang Xintian Pharmaceutical Co.,Ltd.

SZSE:002873.SZ

11.54 (CNY) • At close October 26, 2023
Overview | Financials

Numbers are in millions (except for per share data and ratios) CNY.

2024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q22019 Q12018 Q42018 Q32018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q12015 Q42015 Q32015 Q22015 Q12014 Q42014 Q32014 Q22014 Q1
Revenue 264.377177.322178.317249.759317.151208.756218.439344.696275.322249.216224.58291.233239.375214.657209.085238.999202.482100.38184.098224.431202.674162.135172.255201.782163.811156.411156.225200.402178.1146.987154.205186.128153.86138.993136.314136.314124.642124.642123.168123.168103.895103.895
Cost of Revenue 72.4839.3141.39457.0374.54745.78753.68980.56561.61151.42247.50260.24749.95843.45147.69150.02345.44622.16938.84246.12743.94333.66835.96241.31435.81532.62333.22439.0233.07327.29230.41233.0528.43923.39522.36922.36920.56720.56720.46120.46120.46320.463
Gross Profit 191.898138.012136.922192.729242.603162.969164.75264.132213.711197.794177.078230.986189.417171.206161.394188.977157.03678.211145.256178.304158.731128.467136.293160.468127.996123.789123.002161.383145.027119.695123.793153.078125.421115.599113.945113.945104.075104.075102.707102.70783.43283.432
Gross Profit Ratio 0.7260.7780.7680.7720.7650.7810.7540.7660.7760.7940.7880.7930.7910.7980.7720.7910.7760.7790.7890.7940.7830.7920.7910.7950.7810.7910.7870.8050.8140.8140.8030.8220.8150.8320.8360.8360.8350.8350.8340.8340.8030.803
Reseach & Development Expenses 16.175.23415.21810.0888.8383.999.0134.5654.4173.5898.6623.5996.8281.2887.7591.2572.3361.9421.1258.3716.994.6165.2689.3629.2975.11330.2117.85811.101013.91607.1731.7953.8663.8662.6752.6756.2826.2821.5291.529
General & Administrative Expenses -7.38229.902-61.48890.503-5.10226.535-53.51379.642-11.29430.731-35.64464.167-0.33625.661-29.62625.309-3.7220.921-21.41624.6418.28523.487-4.88220.5164.77822.507-17.80116.3257.04916.376-12.78816.9683.84712.25417.27417.27413.03813.03815.24315.24312.83812.838
Selling & Marketing Expenses 102.65377.3898.73286.587152.01100.21103.834167.167139.053121.925104.847145.112115.917105.948103.041115.76997.26849.79112.48592.13697.91179.327106.51788.84674.64477.35396.485100.84106.33682.26796.36399.1187.02682.91181.881.871.00671.00671.80771.80757.62557.625
SG&A 95.271107.28137.245177.09146.908126.74550.321246.809127.759152.65769.203209.279115.582131.60873.415141.07993.54870.7191.068116.777106.196102.814101.635109.36379.42299.8678.684117.166113.38698.64383.575116.07990.87395.16598.85898.85884.7784.7787.6287.6271.03171.031
Other Expenses -1.382-0.229-0.275-1.19-0.1122.33994.9-42.22946.7812.9878.954-8.3897.248-0.1895.218-0.0680.059-1.9830.138-0.8160.2490.0384.234-0.3642.630.28-6.0480.4968.0122.14412.3231.5836.3840.20900000000
Operating Expenses 162.39114.755151.69139.67206.997133.074154.235209.144178.957159.226156.819180.871157.905135.987146.968144.276127.57674.144147.051128.171134.738110.419137.548121.648114.313103.005121.513121.208133.994101.3119.126118.803107.27397.283102.835102.83586.48486.48489.67389.67373.23373.233
Operating Income 19.1318.546-10.26448.57829.53225.8975.38649.31232.82934.6415.6545.22225.76930.47215.79738.87724.6037.079-4.25845.83521.03220.8261.4337.4715.76319.9239.28737.16112.22616.0362.29630.05115.16914.10212.29412.29416.87716.87713.14813.1489.8569.856
Operating Income Ratio 0.0720.105-0.0580.1940.0930.1240.0250.1430.1190.1390.070.1550.1080.1420.0760.1630.1220.071-0.0230.2040.1040.1280.0080.1860.0960.1270.0590.1850.0690.1090.0150.1610.0990.1010.090.090.1350.1350.1070.1070.0950.095
Total Other Income Expenses Net -1.382-3.852-0.275-1.19-0.1120.252-0.363-0.178-0.025-0.0060.864-5.073-6.702-4.9350.95-5.893-4.7991.029-2.325-5.114-2.7112.8176.919-1.7144.709-0.5811.764-2.524.502-0.225-1.745-2.665-2.876-4.005-3.836-3.836-1.486-1.486-2.36-2.36-2.098-2.098
Income Before Tax 17.74918.317-10.5447.38829.4226.1495.02449.13432.80334.63416.51445.04224.80930.28315.37638.80824.6615.097-4.1245.01921.28220.8645.66337.10618.39320.2033.25337.65515.53518.172.92331.6115.27114.3118.4588.45815.39115.39110.78810.7887.7587.758
Income Before Tax Ratio 0.0670.103-0.0590.190.0930.1250.0230.1430.1190.1390.0740.1550.1040.1410.0740.1620.1220.051-0.0220.2010.1050.1290.0330.1840.1120.1290.0210.1880.0870.1240.0190.170.0990.1030.0620.0620.1230.1230.0880.0880.0750.075
Income Tax Expense 2.9812.745-3.6996.0048.1851.057-6.1911.6946.2353.7544.8422.9463.3394.9172.3292.9562.5711.983-5.90110.8153.6273.6370.1135.1432.6363.077-1.1125.541.2932.776-2.745.0362.5032.2470.4980.4982.3462.3460.4460.4461.5371.537
Net Income 14.76715.572-6.84141.38421.23525.09211.21447.4426.56830.87910.54242.09621.47125.36611.4935.85222.093.1141.83534.56817.67917.345.96632.12715.75717.1264.36532.11514.24315.3945.66326.57412.76812.0647.967.9613.04513.04510.34210.3426.226.22
Net Income Ratio 0.0560.088-0.0380.1660.0670.120.0510.1380.0960.1240.0470.1450.090.1180.0550.150.1090.0310.010.1540.0870.1070.0350.1590.0960.1090.0280.160.080.1050.0370.1430.0830.0870.0580.0580.1050.1050.0840.0840.060.06
EPS 0.0640.067-0.030.180.0920.110.0490.270.150.130.0710.260.130.110.0810.160.140.0140.0110.150.110.0760.0420.160.0960.130.0270.240.120.0890.0460.150.10.070.0460.0460.0760.0760.060.060.0360.036
EPS Diluted 0.0640.062-0.030.170.0920.10.0490.270.150.130.0660.260.130.110.0810.150.140.0140.0110.150.110.0760.0420.160.0960.130.0270.240.120.0890.0460.150.10.070.0460.0460.0760.0760.060.060.0360.036
EBITDA 28.30823.207-16.43652.11235.56230.3198.78255.03534.83238.71419.79450.13130.83735.58513.17244.15630.5252.217-1.46349.75125.81718.4989.16439.28318.79120.2385.79741.35219.35521.1463.85335.65620.37521.97614.68414.68418.39618.39614.80214.80211.37811.378
EBITDA Ratio 0.1070.131-0.0920.2090.1120.1450.040.160.1270.1550.0880.1720.1290.1660.0630.1850.1510.022-0.0080.2220.1270.1140.0530.1950.1150.1290.0370.2060.1090.1440.0250.1920.1320.1580.1080.1080.1480.1480.120.120.110.11